Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Background: Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular...

Full description

Bibliographic Details

Published in:	Lancet Vol. 359; no. 9311; pp. 995 - 1004
Main Authors:	Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf, Björn, Devereux, Richard B, Kjeldsen, Sverre E, Julius, Stevo, Beevers, Gareth
Format:	clinical trial research tables/charts Journal Article
Published:	Lancet 3/23/2002
Online Access:	View this record in EBSCOhost